The phospholipid supplement demonstrated relief in the four primary PMS/PMDD measures
A new clinical study has confirmed the positive effects of Lipogen PMS, a natural phospholipid formulation, in treating and relieving premenstrual syndrome (PMS) symptoms.
PMS defines physical and/or emotional symptoms that occur one to two weeks before a woman’s period.
A randomised, double-blind, placebo-controlled clinical study was directed by Juliane Hellhammer, PhD, the CEO of daacro GmbH & Co. KG, a contract research organisation (CRO) in Trier, Germany.
The research, published in Clinical Nutrition ESPEN in February 2018, evaluated 40 women aged 18-45 who were diagnosed with PMS by their physicians.
The Lipogen PMS treatment group experienced an ongoing reduction in premenstrual syndrome symptoms, whereas the placebo group returned to initial PMS-symptom levels.
Dr Hellhammer says: “I am quite impressed that a natural, non-pharmaceutical product has promising potential for relieving women’s PMS symptoms.”
The study observed women during an initial baseline menstrual cycle followed by three menstrual cycles in which subjects received daily treatment of the Lipogen PMS complex of 400 mg phosphatidylserine (PS) and 400 mg phosphatidic acid (PA).
Treatment compliance was monitored with an electronic medication event monitoring system (MEMS).
Using the standardised DRSP (Daily Record of Severity of Problems) scale, the study showed Lipogen PMS improved symptoms in the four primary measures (p=0.001):
Lipogen PMS, patented in the US, Europe and Japan, is all-natural and has earned both US FDA GRAS status and EU EFSA Novel Food approval. Lipogen is considering further developing the product as a botanical drug.
According to the American Family Physician Journal, 20–30% of women of child-bearing age experience PMS, while PMDD (premenstrual dysphoric disorder) affects 3–8% of premenopausal women.
The latest research published by Credence Research reported that the global PMS treatment market was valued at $4.2 billion in 2015, and is expected to reach $5.0 billion by 2024, expanding at a CAGR of 2.0% from 2016 to 2024.
“This breakthrough research in relieving women’s PMS symptoms is relevant to a large segment of the population,” says David Rutenberg, CEO of Lipogen. “The new Lipogen PMS product may help women as a natural solution for controlling PMS symptoms.”